Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy

Figures & data

Figure 1 PSOLife CARE program structure.

Abbreviation: QOL, quality of life.

Table 1 Patient Satisfaction Questionnaire

Question	Response
1). Have you been advised with clear and fully explained information about the services provided within the Program to easily activate them?	Score ^a
2). How do you define the quality of the Program?	Score ^a
3). Do you feel more confident in drug administration and management thanks to this Program?	Score ^a
4). Do you find this Program helpful in following the Clinical Centre’s recommendations?	Score ^a
5). Do you feel supported by this Program in dealing with the management of your psoriasis?	Score ^a
6). Do you think the Program should be changed in some way?	Yes/No

Notes: ^a1 – Did not meet my expectations; 2 – Fairly Satisfactory; 3 – Satisfactory; 4 – Very Satisfactory; 5 – Outstanding.

Table 2 Medical Professional Satisfaction Questionnaire

Question	Response
1). Do you find this Program the most suitable solution to deal with patients in treatment with secukinumab?	Score ^a
2). In which of the following aspects do you feel more supported?
a. Is the patient more followed and aware?	Yes/No
b. Are the monitoring visits taking less time?	Yes/No
c. Could you get more information about the patients’ disease management?	Yes/No
d. Any other relevant aspect?	Yes/No
3). If Yes to question 2a, in which aspect do you find the patient more followed and aware?
a. Management of secukinumab	%
b. Management of side effects	%
c. Management of the dermatological aspect	%
d. Management of the psychological aspect	%
e. Management of the nutritional aspect	%
f. Others	%
4). If Yes to question 2b, what is the average time saved at each monitoring visit?
a. <5 minutes	%
b. 5–10 minutes	%
c. 10–20 minutes	%
d. >20 minutes	%
5). If Yes to question 2c, which kind of information did you get thanks to the Program?
a. Patient adherence	%
b. Compliance with the recommendations	%
c. Side effects	%
d. Other? If yes, which aspects could you mention?	%
6). If Yes to question 2d, which kind of information could you get thanks to the Program in addition to the ones yet mentioned?
7). What is your opinion about the overall quality of the Program?	Score ^a

Notes: ^a1 – Did not meet my expectations; 2 – Fairly Satisfactory; 3 – Satisfactory; 4 – Very Satisfactory; 5 – Outstanding.

Table 3 Patient Adherence Questionnaire

Question	Response
1. After some time out of the Program, in which of the following aspects do you think the PSOLife Program’s calls have been helpful?
a. Therapy Adherence	%
b. Organization/Reminder of the visits	%
c. Emotional Support	%
2. How do you consider/assess your therapy adherence since you are no longer under the Program?
a. Excellent (>95%)	%
b. Good (>80% to <95%)	%
c. Low (<80%)	%
3. Are you still under treatment with secukinumab?	Yes/No
4. If No, specify the motivation
a. Not needed	%
b. Switch to a similar biologic drug	%
c. Change of therapy	%

Figure 2 Uptake of patients and Clinical Centers into the PSOLife CARE Program.

Table 4 Average Time Period in Months Between the Date Patients First Received Secukinumab (Therapy Start Date) and the Date Patients Were Enrolled in the Program (Program Start Date)

	Time Period, Months	No. of Patients^a
April 2017–September 2017	5.7	69
October 2017–March 2018	3.4	108
April 2018–September 2018	4.2	79
October 2018–March 2019	5.3	133
April 2019–September 2019	3.4	75
October 2019–March 2020	0.7	39
April 2020–September 2020	0.6	9

Notes: ^aData was calculated on 512 patients as this data was not available for 13 patients.

Figure 3 Overall patient satisfaction with the PSOLife CARE Program per treatment period.

Notes: Satisfaction score: 1 – Did not meet my expectations; 2 – Fairly Satisfactory; 3 – Satisfactory; 4 – Very Satisfactory; 5 – Outstanding.

Figure 4 The (A) emotional, (B) social, (C) physical, and (D) economic impact of psoriasis on patients’ quality of life over a 24-month detection period during the PSOLife CARE Program.

Figure 5 Treatment adherence at (A–D) 12 months (n=82) and (E–H) 24 months (n=182).